Pandorum, Bharat Biotech Unit Ink APAC Exosome Therapy Manufacturing Pact

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Pandorum, Bharat Biotech Unit Ink APAC Exosome Therapy Manufacturing Pact
Overview

Pandorum Technologies has partnered with Nucelion Therapeutics, a Bharat Biotech subsidiary, to expand manufacturing of its exosome-based regenerative therapies. The collaboration targets the Asia-Pacific region, aiming to boost regional supply and regulatory readiness for novel treatments of ocular diseases.

Regenerative Therapy Expansion

Pandorum Technologies, a firm developing programmable tissue regeneration platforms, has entered a significant collaboration with Nucelion Therapeutics. Nucelion, an arm of Bharat Biotech, will bolster Pandorum's manufacturing capabilities for its exosome-based therapeutic platform, focusing initially on the Asia-Pacific (APAC) region.

Boosting Regional Supply Chains

This strategic alliance aims to enhance Pandorum's regional supply and regulatory preparedness. "Nucelion Therapeutics brings strong expertise in advanced biologics manufacturing and a high-quality operational environment that aligns well with our long-term vision," stated Tuhin Bhowmick, PhD, Co-Founder and CEO of Pandorum Technologies. The partnership is seen as a critical step in delivering advanced therapies globally.

Focus on Ocular Diseases

Nucelion Therapeutics expressed enthusiasm for developing "Kuragenx," Pandorum's innovative exosome therapy. This novel treatment holds potential to transform the standard of care for ocular diseases. Raghu Malapaka, CBO at Nucelion Therapeutics, highlighted their advanced manufacturing platforms' ability to support complex biologics for scalable production across APAC.

'Make in India' Momentum

The collaboration also signals progress for India's biotech sector. Jitendra Kumar, Managing Director at BIRAC, Dept of Biotechnology, Govt of India, noted that the Pandorum-Nucelion partnership demonstrates readiness for both innovation and domestic manufacturing to address global unmet clinical needs.

Expanding Therapeutic Horizons

While current programs address ocular surface injury and inflammatory corneal diseases, including Stevens-Johnson syndrome and Neurotrophic Keratitis, Pandorum plans future applications. These include treatments for degenerative changes in skin, pulmonary, and other organ systems affected by inflammation, vascular pathologies, and fibrosis. Nucelion Therapeutics, as a wholly owned subsidiary of Bharat Biotech, provides end-to-end manufacturing support, from process scale-up to GMP-compliant production of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.